Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder marked by motor and autonomic dysfunction, with unknown cause and mostly sporadic cases. It involves alpha-synuclein buildup in myelin-producing oligodendroglial cells. The term "MSA" was adopted in 1969 to unify three related conditions&mdash;Shy&ndash;Drager syndrome, Striatonigral Degeneration, and Olivopontocerebellar Atrophy&mdash;due to their overlapping symptoms.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Diagnosed Prevalent Cases of MSA&nbsp;
</li>
<li dir="ltr" aria-level="1">
Gender-specific Diagnosed Prevalent Cases of MSA&nbsp;
</li>
<li dir="ltr" aria-level="1">
Age-specific Diagnosed Prevalent Cases of MSA&nbsp;
</li>
<li dir="ltr" aria-level="1">
Type-specific Diagnosed Prevalent Cases of MSA&nbsp;
</li>
<li dir="ltr" aria-level="1">
Stage-specific Diagnosed Prevalent Cases of MSA
</li>
<li dir="ltr" aria-level="1">
nOH Symptomatic Cases of MSA
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-epidemiology-forecast">Multiple System Atrophy Epidemiology</a></h2>
<ul>
<li dir="ltr" aria-level="1">
In 2023, there were approximately 71K prevalent cases of MSA in the 7MM.
</li>
<li dir="ltr" aria-level="1">
In 2023, the U.S. reported the highest MSA prevalence among the 7MM, with approximately 42.5K cases, projected to grow at a CAGR of 1.0% through 2034.
</li>
<li dir="ltr" aria-level="1">
Germany led the EU4 and the UK with around 2.7K cases, followed by the UK (~2.4K) and Spain (~1.5K).
</li>
<li dir="ltr" aria-level="1">
Japan reported about 5.1K male and 12K female MSA cases in 2023, with numbers expected to increase by 2034.
</li>
<li dir="ltr" aria-level="1">
In the U.S., stage-wise MSA cases in 2023 were: ~400 (stage 0), ~800 (stage 1), ~2.1K (stage 2), ~15K (stage 3), ~13K (stage 4), and ~10K (stage 5).
</li>
<li dir="ltr" aria-level="1">
In Japan, MSA-C was more prevalent, accounting for 70% of cases, while MSA-P represented 30%.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market">Multiple System Atrophy Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2023, the MSA market in the 7MM was valued at ~USD 43 million and is projected to grow at a CAGR of 44.7% through 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. dominated with ~USD 38 million (88% of the market), driven by upcoming therapies.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK contributed ~USD 2.3 million, led by Germany (~USD 0.57M), the UK (~USD 0.50M), and Spain (~USD 0.32M).
</li>
</ul>
<h3 dir="ltr">Multiple System Atrophy Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Increased recognition of MSA&rsquo;s clinical features is leading to earlier diagnosis and more accurate case identification.
</li>
<li dir="ltr" aria-level="1">
A growing number of clinical trials and promising pipeline candidates are boosting market interest and investment.
</li>
<li dir="ltr" aria-level="1">
The lack of disease-modifying treatments creates strong demand for novel therapies, encouraging innovation and accelerated development.
</li>
</ul>
<h3 dir="ltr">Multiple System Atrophy Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
MSA is often misdiagnosed due to symptom overlap with Parkinson&rsquo;s disease and other movement disorders, delaying proper treatment.
</li>
<li dir="ltr" aria-level="1">
Current therapies are largely symptomatic, with no approved disease-modifying drugs, hindering market growth.
</li>
<li dir="ltr" aria-level="1">
As a rare disease, the limited patient pool poses challenges for large-scale clinical trials and commercial viability.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight">Multiple System Atrophy Therapies</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Lu AF82422
</li>
<li dir="ltr" aria-level="1">
AAV2-GDNF Gene Therapy
</li>
<li dir="ltr" aria-level="1">
Ampreloxetine (TD-9855)
</li>
<li dir="ltr" aria-level="1">
ONO-2808
</li>
<li dir="ltr" aria-level="1">
ION464
</li>
<li dir="ltr" aria-level="1">
ATH434
</li>
<li dir="ltr" aria-level="1">
Emrusolmin
</li>
</ul>
And others.
<h3 dir="ltr">Multiple System Atrophy Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
H Lundbeck A/S
</li>
<li dir="ltr" aria-level="1">
Brain Neurotherapy Bio, Inc.
</li>
<li dir="ltr" aria-level="1">
Asklepios BioPharmaceutical, Inc.
</li>
<li dir="ltr" aria-level="1">
Theravance Biopharma
</li>
<li dir="ltr" aria-level="1">
Ono Pharmaceutical Co. Ltd
</li>
<li dir="ltr" aria-level="1">
Ionis Pharmaceuticals, Inc.
</li>
<li dir="ltr" aria-level="1">
Biogen
</li>
<li dir="ltr" aria-level="1">
Alterity Therapeutics
</li>
<li dir="ltr" aria-level="1">
Teva Pharmaceutical
</li>
<li dir="ltr" aria-level="1">
MODAG GmbH
</li>
</ul>
And others.

Multiple System Atrophy Market

Multiple System Atrophy Market Infographics

Multiple System Atrophy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape